Galera Therapeutics (NASDAQ: GRTX) agrees to merge with Obsidian; S-4 filed

Rhea-AI Filing Summary

Galera Therapeutics, Inc. announced a proposed merger with Obsidian Therapeutics under an Agreement and Plan of Merger dated April 14, 2026. The parties state the transaction will combine Galera and Obsidian as wholly owned subsidiaries of a newly formed parent and that a registration statement on Form S-4 (the Prospectus) has been filed to provide information to Galera stockholders.

The communication notes the Prospectus will be mailed to Galera stockholders and urges careful review of the registration statement and prospectus. It disclaims any offer or solicitation and identifies directors and officers of Galera and Obsidian as possible participants in any proxy solicitation. The filing contains customary forward-looking statements and references Galera’s prior SEC filings for risk factors.

Insights

M&A Counsel

Deal mechanics: merger agreement dated April 14, 2026 with Form S-4 filed.

The filing confirms a bilateral merger structure where Galera and Obsidian will become subsidiaries of a newly formed parent, governed by the Agreement and Plan of Merger dated April 14, 2026. The Form S-4 serves as an information statement for Galera and a prospectus for the new company.

Key legal dependencies are typical: stockholder approval, satisfaction or waiver of closing conditions, and completion of a disclosed private placement financing. Timing and closing conditions are described as subject to those conditions; specific closing dates and financing terms are not provided in the excerpt.

Biotech Corporate Strategy Analyst

Strategic combination disclosed; public disclosure via Form S-4 underway.

The press material frames the transaction as a consolidation of pipelines through a parent company and states the Prospectus will be distributed to Galera stockholders. Management and directors are named as possible solicitation participants, which is standard for a negotiated transaction.

Material operational impacts, financing size, and expected product synergies are described only as forward-looking; concrete financial or clinical milestones are not quantified in the provided excerpt, so substantive commercial effects await the Prospectus and subsequent filings.

Key Figures

Merger agreement date: April 14, 2026 Filing date: May 21, 2026 SEC File No.: 001-39114

3 metrics

Merger agreement date April 14, 2026 Agreement and Plan of Merger dated April 14, 2026

Filing date May 21, 2026 Date of this communication

SEC File No. 001-39114 Filer’s SEC File Number

Key Terms

Form S-4, Prospectus, forward-looking statements, proxy solicitation

4 terms

Form S-4 regulatory

"The newly formed company has filed a registration statement on Form S-4"

A Form S-4 is a legal document that companies file with the government to announce and explain a major business move, such as a merger or acquisition. It provides detailed information to help investors understand how the deal might affect the company's value and future prospects, similar to a detailed blueprint that clarifies the impact of a significant change.

Prospectus financial

"The newly formed company has filed a registration statement on Form S-4 that includes information statement and prospectus"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

forward-looking statements regulatory

"This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

proxy solicitation regulatory

"Galera and Obsidian and each of their respective directors and executive officers may be considered participants in the solicitation of proxies"

Proxy solicitation is the process of asking shareholders for permission to vote their shares on corporate matters, usually by sending voting forms or requests by mail, email or phone. Investors should watch proxy solicitations because they signal attempts to change control, influence board elections or approve big deals — like neighbors organizing votes on a shared building project — and the outcome can materially affect a company’s strategy and stock value.

Filed by Galera Therapeutics, Inc.

pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

under the Securities Exchange Act of 1934

Subject Company: Galera Therapeutics, Inc.

Filer’s SEC File No.: 001-39114

Date: May 21, 2026

This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of April 14, 2026, by and among Galera Therapeutics, Inc., a Delaware corporation (“Galera”), Obsidian Therapeutics, Inc., a Delaware corporation (“Obsidian”), Gazelle Parent, Inc., a Delaware corporation (“Parent”), Onyx MergerSub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Obsidian Merger Sub”), and Gazelle Merger Subsidiary, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Galera Merger Sub”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Galera will be merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the “Galera Merger”), and Obsidian will be merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent.

The following social media post was posted by Obsidian on LinkedIn on May 21, 2026.

Additional Information and Where to Find It

In connection with the proposed transactions between Obsidian and Galera Therapeutics, Inc. (“Galera”), Galera and the newly formed company formed in connection therewith will file relevant materials with the SEC. The newly formed company has filed a registration statement on Form S-4 that includes information statement and prospectus relating to the proposed transaction, which constitutes an information statement of Galera and a prospectus of the newly formed company (the “Prospectus”). Galera and the newly formed company may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the Prospectus or any other document which Galera or the newly formed company may file with the SEC or send to stockholders of Galera or Obsidian in connection with the proposed transaction. The Prospectus will be mailed to stockholders of Galera. INVESTORS AND SECURITYHOLDERS OF GALERA ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROSPECTUS AND ALL OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GALERA, OBSIDIAN AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of the registration statement and the Prospectus (when available) and other documents filed with the SEC by Galera or the newly formed company through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Galera will be available free of charge on Galera’s website at www.galeratx.com.

No Offer or Solicitation

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell, any securities of Galera, Obsidian or the newly formed company, or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Participants in the Solicitation

This communication is not a solicitation of a proxy from any security holder of Galera or Obsidian. However, Galera and Obsidian and each of their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Galera may be found in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 19, 2026 and its proxy statement for its 2026 annual meeting of stockholders, which was filed with the SEC on April 10, 2026. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in Prospectus and other relevant materials to be filed with the SEC when they become available.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning future clinical development activities, potential milestone payments, the merger transaction and completion of the concurrent private placement financing, the expected effects, perceived benefits or opportunities and related timing with respect thereto and expectations regarding or plans for the combined company’s pipeline.

These forward-looking statements relate to Galera, Obsidian and the newly formed company (together, “us” or “we”), our business prospects and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in Galera’s Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise, except as required by applicable law.

These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: statements about the synergies or benefits of the proposed transaction, including future financial and operating results, plans, objectives, expectations and intentions; the anticipated timing of closing of the proposed transaction and the private placement financing; negative effects of the announcement or consummation of the proposed transaction on the market price of our capital stock and our operating results; risks relating to the value of shares of the newly formed company to be issued in the proposed transaction; risks related to the ability to obtain approval of the Galera stockholders; changes in capital resource requirements; risks related to our inability to obtain sufficient additional capital to continue to advance our product candidates; our and our collaborators’ ability to execute clinical programs for our product candidates; timing, progress, enrollment or results of clinical trials with our product candidates; our ability to obtain and maintain intellectual property rights and regulatory exclusivities; and our ability to establish a market for our product candidates if the combined company receives regulatory approval therefor.

FAQ

What did Galera Therapeutics (GRTX) disclose about the transaction?

Galera disclosed a proposed merger with Obsidian under an Agreement and Plan of Merger dated April 14, 2026. The parties filed a Form S-4 registration statement that includes a prospectus and information statement for stockholders.

Will Galera stockholders receive transaction documents?

Yes. The Prospectus included in the Form S-4 will be mailed to Galera stockholders. It contains important information about the proposed transaction and related details for voting and review.

Does this filing constitute an offer to buy or sell securities?

No. The communication expressly states it is for informational purposes only and is not an offer to sell or a solicitation to buy securities. Any offer would be made only by means of a prospectus meeting legal requirements.

Who are considered participants in the solicitation?

Galera, Obsidian and their respective directors and executive officers may be considered participants in any proxy solicitation. Further details about participants and their interests will appear in the Prospectus and related SEC filings.

Where can investors obtain the registration statement and prospectus?

Investors may obtain free copies of the registration statement and Prospectus on the SEC website at www.sec.gov and on Galera’s website at www.galeratx.com when filed and available.